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Abstract
Background: During pneumonia, inflammation and coagulation are activated as part of anti-bacterial host defense.
Activated protein C (APC) has anticoagulant and anti-inflammatory properties and until recently was a registered
drug for the treatment of severe sepsis. Streptococcus (S.) pneumoniae is the most common causative pathogen in
community-acquired pneumonia.
Methods: We aimed to investigate the effect of high APC levels during experimental pneumococcal pneumonia.
Wild type (WT) and APC overexpressing (APChigh)-mice were intranasally infected with S. pneumoniae and sacrificed
after 6, 24 or 48 hours, or followed in a survival study.
Results: In comparison to WT mice, APChigh-mice showed decreased bacterial dissemination to liver and spleen,
while no differences in bacterial loads were detected at the primary site of infection. Although no differences in the
extent of lung histopathology were seen, APChigh-mice showed a significantly decreased recruitment of neutrophils
into lung tissue and bronchoalveolar lavage fluid. Activation of coagulation was not altered in APChigh-mice. No
differences in survival were observed between WT and APChigh-mice (P =0.06).
Conclusion: APC overexpression improves host defense during experimental pneumococcal pneumonia. This
knowledge may add to a better understanding of the regulation of the inflammatory and procoagulant responses
during severe Gram-positive pneumonia.
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Background
The most common cause of community-acquired pneu-
monia (CAP) is infection with the pathogen Streptococcus
(S.) pneumoniae [1,2]. CAP often leads to severe sepsis
and a recent study in sepsis patients showed that 35.6% of
the cases were caused by severe CAP [3]. Pneumonia
caused by S. pneumoniae and related pneumococcal sepsis
are among the most common causes of death in the West-
ern world rendering them a serious threat to health [4]
and stressing the importance of understanding host
defense mechanisms during this disease.
Over the last years many studies have demonstrated that
the host response during severe (pneumococcal) pneumo-
nia and sepsis consists of a strong pro-inflammatory
response together with increased procoagulant activity,
blunted anticoagulant mechanisms and suppression of the
fibrinolytic system [2,5,6]. The interplay between inflam-
mation and blood coagulation is considered to be an es-
sential part of the host defense against infectious agents, a
concept recently referred to as ‘immunothrombosis’ [7].
Activated protein C (APC) serves as one of the main
inhibitors of the coagulation system via its capacity to in-
activate coagulation factors Va and VIIIa. Additionally, in
the last decade APC has gained much interest for its cyto-
protective, anti-inflammatory, anti-apoptotic and vascular
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barrier-protective properties, which are largely mediated
by the protease activated receptor-1 (PAR1) and the endo-
thelial PC receptor (EPCR) [8,9]. Much research has been
done on the effect and role of APC during (pneumo)sep-
sis. In patients with severe pneumonia and sepsis, a correl-
ation was observed between low PC and APC levels and
the occurrence of organ dysfunction and adverse outcome,
pointing to a protective role for APC [10-12]. Moreover,
in the PROWESS study treatment of severe sepsis patients
with intravenous recombinant human APC (rhAPC) re-
duced mortality [13] and patients with sepsis caused by S.
pneumoniae pneumonia were among those with the lar-
gest benefit from rhAPC treatment [14,15]. Despite these
positive results, post-marketing studies failed to show
similar protective effects of APC [16] and a recently com-
pleted confirmatory trial in septic shock patients did not
show any benefit from APC treatment [17], leading to the
withdrawal of this compound from the market [18].
Our laboratory recently showed protective effects
of APC during pneumococcal pneumonia. Therapeutic
administration of recombinant murine APC (rmAPC) at-
tenuated pulmonary coagulopathy and improved survival
during infection with S. pneumoniae [19], whereas early
administration of rmAPC also had anti-inflammatory ef-
fects as reflected by reduced levels of pro-inflammatory
cytokines in lungs of rmAPC-treated mice [20]. A pos-
sible limitation of these studies is the variability of
rmAPC concentrations, due to its short half-live and the
fact that in these studies rmAPC was administered only
every 8 hours. To mimic the clinical situation more reli-
ably, it would be better to administer rmAPC via con-
tinuous intravenous infusion. However, this is difficult to
achieve in freely moving mice. Therefore, in the present
study we used mice with sustained elevated levels of
APC due to endogenous overexpression of hyperactiva-
table PC (APChigh-mice [21]) and investigated the effects
of elevated APC levels in the same model of pneumo-
coccal pneumonia [19,20]. We here show that sustained
elevated levels of APC exert protective effects during
pneumococcal pneumonia, as evidenced by decreased
bacterial dissemination to distant body sites and de-




Pathogen-free 10-week old female wild type (WT) C57BL/
6 mice were purchased from Charles River (Maastricht,
The Netherlands) and maintained in cages with 3–6 mice
at the animal care facility of the Academic Medical Center
(University of Amsterdam), according to national guide-
lines with free access to food and water. APChigh-mice on
a C57BL/6 genetic background were generated as de-
scribed [21] and bred in the animal facility of the
Academic Medical Center in Amsterdam. WT and
APChigh-mice were housed separately. Wellfare of the
mice during the experiment was checked twice daily.
As reported earlier, transgenic APChigh mice appear
grossly normal, reproduce normally and do not show
any signs of spontaneous bleeding [21]. Endogenous
overexpression of APC in APChigh mice has been con-
firmed in previous reports [21] as well as in our own
laboratory [22]. Per time-point two groups of 8 mice
were compared (WT and APChigh). The number of 8
mice per group was carefully chosen as with this num-
ber the Wilcoxon (Mann–Whitney) rank test gives a
power of 80% and a chance of 0.904 that the observed
mean in one group is lower than in the other group,
demonstrated with a two-sided level of significance of
0.05. Moreover, this group size provided us statistical sig-
nificance for differences we consider clinically relevant.
Ethics statement
Mice studies were carried out under the guidance of the
Animal Research Institute of the Academical Medical
Center in Amsterdam (ARIA). All animals were main-
tained at the animal care facility of the Academic
Medical Center (University of Amsterdam), with free ac-
cess to food and water, according to National Guidelines
for the Care and Use of Laboratory Animals, which are
based on the National Experiments on Animals Act
(Wet op de Dierproeven (WOD)) and the Experiments
on Animals Decree (Dierproevenbesluit), under the
jurisdiction of the Ministry of Public Health, Welfare
and Sports, the Netherlands. The Committee of Animal
Care and Use (Dier Experimenten Commissie, DEC) of
the University of Amsterdam approved all experiments
(Permit number DIX100121-101787).
Experimental infection and determination of bacterial
growth
Pneumonia was induced by intranasal inoculation of all
mice at the same time point of 5*104 colony forming
units (CFU) in 50 μl 0.9% NaCl of S. pneumoniae serotype
3 (ATCC strain 6303; American Type Culture Collection,
Rockville, MD) as previously described [19,20]. Mice were
sacrificed after 6, 24 or 48 hours (n = 8/group) and sur-
vival studies (n =16/group for WT mice and 12/group for
APChigh-mice) were performed in which mortality was
assessed every 6 hours. Sample harvesting, processing and
determination of bacterial growth were done as described
[19,20]. Briefly, mice were sacrificed under intraperitoneal
anesthesia containing ketamin (Eurovet Animal Health,
Bladel, The Netherlands) and medetomidin (Pfizer Animal
Health Care, Capelle aan den IJssel, The Netherlands).
Blood was drawn from the vena cava inferior into syringes
containing sodium citrate (4:1 vol/vol) and stored on ice.
Left lungs, spleen and liver were harvested, weighed and
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homogenized at 4°C in 4 volumes of sterile saline using a
tissue homogenizer (Pro200, Pro Scientific Inc., Oxford,
CT) and processed as described below. CFU were deter-
mined from serial dilutions of organ homogenates and
blood plated on blood agar plates and incubated at 37°C
5% CO2 for 20 h before colonies were counted. Bronchoal-
veolar lavage fluid (BALF) was harvested by selectively
cannulation of the right main bronchus with a 22-gauge
Abbocath-T catheter (Abott, Sligo, Ireland) followed by
unilateral lavage of the right lung with three 300 μl ali-
quots of sterile phosphate-buffered saline. Harvested cells
were kept on ice until analysis.
Assays
Lung homogenates were diluted 1:2 in lysis buffer con-
taining 300 mM NaCl, 30 mM Tris, 2 mM MgCl2,
2 mM CaCl2, 1% Triton X-100 and protease inhibitor
cocktail (Roche, Indianapolis, IN) and incubated at 4°C
for 30 min and centrifuged at 680 g at 4°C for 10 min.
Lung homogenates were stored at −20°C until analysis.
Blood was centrifuged at 600 g and plasma was snap fro-
zen in liquid nitrogen and stored at −80°C until analysis.
Interleukin (IL)-6, IL-10, IL-12p70, interferon (IFN)-γ
and monocyte-chemoattractant protein (MCP)-1 were
measured by cytometric bead array (CBA) multiplex
assay (BD Biosciences, San Jose, CA) in accordance
with the manufacturers’ recommendations. Tumor ne-
crosis factor-α (TNF-α; R&D systems, Minneapolis,
MN), keratinocyte-derived chemokine (KC; R&D sys-
tems, Minneapolis, MN) and thrombin-antithrombin
complexes (TATc; Siemens Healthcare Diagnostics,
Marburg, Germany) were measured with commercially
available ELISA kits according to the manufacturers’
instructions.
Histology and immunohistochemistry
Paraffin-embedded 4 μm lung sections were stained with
haematoxylin and eosin (H&E) and analyzed for inflam-
mation and tissue damage, as described previously
[19,20]. All slides were scored by an experienced histo-
pathologist blinded for experimental groups for the fol-
lowing parameters: bronchitis, interstitial inflammation,
edema, endothelialitis, pleuritis and thrombus formation.
All parameters were rated separately from 0 (condition
absent) to 4 (most severe condition). The total histopath-
ology score was expressed as the sum of the scores of the
individual parameters, with a maximum of 24. Staining for
granulocytes, using fluorescein isothiocyanate-labeled rat-
anti-mouse Ly-6G mAb (BD Pharmingen, San Diego, CA)
was performed as described previously [22,23]. All slides
were slightly counterstained with methylgreen. The total
tissue area of Ly-6G stained slides was scanned with a
slide scanner (Olympus dotSlide, Tokyo, Japan) and the
obtained scans were exported in TIFF format for digital
image analysis. The digital images were analyzed with
ImageJ (version 2006.02.01, National Institutes of Health,
Bethesda, MD) and the immunopositive (Ly6G+) area cal-
culated from an average of 10 images per lung was
expressed as the percentage of the total lung surface area.
Cell counts and differentials
Freshly harvested BALF-cells were counted using an
automatic haemocytometer (Beckman Coulter, Fullerton,
CA). Differential counts were performed on cytospins
stained with a modified Giemsa stain (Diff-Quick, Dade
Behring, Düdingen, Switzerland).
Statistical analysis
All data are expressed as box and whisker plots showing
the smallest observation, lower quartile, median, upper
quartile and largest observation. Comparisons between
groups were performed using a Mann–Whitney U test.
For survival studies Kaplan-Meier analyses followed by
log rank test were performed. All analyses were done
using GraphPad Prism version 5.01 (GraphPad Software,
San Diego, CA). P-values <0.05 were considered statisti-
cally significant.
Results
APC-overexpression hampers bacterial dissemination
We previously showed that APChigh-mice have markedly
increased levels of APC in various organs as was measured
in plasma, lung-, kidney-, liver-, and spleen homogenates
of uninfected APChigh-mice [22]. To investigate whether
overexpression of APC would impact on bacterial growth,
we infected WT and APChigh-mice with 5*104 CFU of S.
pneumoniae and sacrificed them after 6, 24 or 48 hours to
determine bacterial loads in lungs (the primary site of in-
fection), blood, liver and spleen homogenates (to evaluate
the extent of dissemination) (Figure 1). No differences in
bacterial growth were seen in the lungs (Figure 1A) or
blood (Figure 1B) between WT and APChigh-mice. How-
ever, relative to WT mice, APChigh-mice showed markedly
decreased bacterial loads 24 and 48 hours after infection
in both liver (Figure 1C; P <0.05 for both time points) and
spleen homogenates (Figure 1D; P <0.01 for both time
points). These data indicate that overexpression of APC
hampers bacterial dissemination during S. pneumoniae-in-
duced pneumonia.
APC-overexpression does not impact on lung pathology
during pneumococcal pneumonia but is associated with
decreased neutrophil influx
Our model of pneumococcal pneumonia is associated
with profound lung pathology [19,20,24]. Both WT and
APChigh-mice infected with S. pneumoniae showed inflam-
matory infiltrates in the lungs characterized by bronchitis,
interstitial inflammation, oedema, endothelialitis, pleuritis
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and thrombus formation (Figure 2A-C). However, APC-
overexpression did not induce differences in lung path-
ology during infection between WT and APChigh-mice
(Figure 2A). Neutrophils contribute to host defense
against S. pneumoniae [19,20]. In order to investigate neu-
trophil influx in our model we measured percentage of
Ly-6G staining in infected lung tissue (Figure 2D-F).
Twenty-four hours after infection, APChigh-mice displayed
significantly decreased neutrophil numbers in their lungs
as compared to WT mice (P <0.05; Figure 2D-F). These
data were confirmed by decreased numbers of total cell
counts in BALF in APChigh-mice compared to WT mice
(P <0.01; Figure 2G), for which a decrease in the number
of neutrophils in APChigh-mice mainly was responsible
(P <0.01; Figure 2H). BALF macrophage and lymphocyte
numbers did not differ between APChigh and WT mice
(Figure 2I-J).
Limited differences between WT and APChigh-mice in
cytokine production
Since cytokines are important regulators of the host
immune response during pneumococcal pneumonia [1,2]
we measured levels of the following cytokines in lung
homogenates and plasma: TNF-α, IL-6, IL-10, IL-12p70,
IFN-γ, MCP-1 and KC (Table 1). The lung and plasma
levels of these mediators did not differ between mouse
strains at 6, 24 or 48 hours after infection.
Overexpression of APC does not inhibit coagulation
activation
To obtain insight into the anticoagulant potential of
overexpression of APC we measured the levels of TATc,
a parameter of coagulation-induction. TATc was mea-
sured in in lung homogenates and plasma of WT and
APChigh-mice 6 and 48 hours after inoculation with S.
pneumoniae (Figure 3). No differences in TATc levels
between WT and APChigh-mice were observed either in
the pulmonary or the systemic compartment.
APChigh-mice show a trend towards a better survival
during experimental pneumococcal pneumonia
We have previously shown that in our model of pneumo-
coccal pneumonia is associated with a high mortality [19].
To investigate whether overexpression of APC impacts
mortality during pneumococcal pneumonia we intrana-
sally infected WT and APChigh-mice with 5*104 CFU of S.
pneumoniae and observed them during the following
8 days (Figure 4). In line with the decreased bacterial bur-
dens observed in liver and spleen homogenates, and the
less prominent cellular influx in the lung, APChigh-mice
showed a trend towards a better survival when compared
to WT mice (P =0.06).
Discussion
The potential of the PC system as a pharmaceutical target
in sepsis remains a topic of debate despite the retraction
Figure 1 APC-overexpression is associated with reduced bacterial dissemination. Mice were intranasally inoculated with 5*104 CFU of S.
pneumoniae and sacrificed after 6, 24 or 48 hours. Bacterial loads were determined in lung homogenates (A), blood (B), liver homogenates
(C) and spleen homogenates (D). Data are expressed as box and whisker plots showing the smallest observation, lower quartile, median, upper
quartile and largest observation. Grey boxes represent WT mice, white boxes represent APChigh-mice (n =8 mice per group for each time point).
*P <0.05 and **P <0.01 for the difference between WT and APChigh-mice (Mann–Whitney U test). BD below detection limits.
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of recombinant human APC from the market due to
efficacy concerns [13,17,18,25-27]. In the pulmonary com-
partment, increased coagulation activation during pneu-
monia may be advantageous for the host by preventing
potential lethal bleeding from destructed lung tissue and
by providing a platform to encounter, entrap and kill in-
vading pathogens [7]. In contrast, inflammation-induced
coagulation activation can also produce collateral damage
and be detrimental by interfering with normal organ
physiology and hampering a balanced immune re-
sponse [5,6,28]. APC has both anticoagulant and anti-
inflammatory effects [8,9] and thereby can be expected
to influence the host response during infection [8,9].
Our goal was to address the impact of sustained ele-
vated levels of APC in a clinically relevant pneumonia
model by using APChigh-mice with high endogenous
hyperactivatable PC expression [21].
The results of our study show that in S. pneumoniae-
induced pneumonia APChigh-mice have an improved
host defense as reflected by decreased dissemination of
bacteria to distant organs and an attenuated influx of
neutrophils into the lungs. In the ‘PROWESS’ human
sepsis trial, rhAPC treatment was especially beneficial in
the sepsis group with pneumonia [13,14]. Therefore, we
focused this and our previous studies [19,20] on effects
of APC in the pulmonary compartment and CAP, with
S. pneumoniae as the clinically most relevant pathogen
[1,2]. The APChigh-mice used in this study overexpress
hyperactivatable human PC [21]. In this respect, gener-
ation of APC is dependent on thrombin, yet less
dependent on thrombomodulin (which is downregulated
in sepsis), thereby conferring some “clot-specificity”.
Therefore, overexpression in APChigh-mice is different
from infusing recombinant APC per se. Nevertheless,
because there is constitutive thrombin generation, the
animals show constitutively elevated APC at a concen-
tration that is very similar to the dosing used in clinical
trials (45 ng/ml steady state) [29].
Likewise, inhibition of neutrophil attraction by APC was
shown in other human and animal studies in different
inflammatory settings [30-34]. Treatment with rhAPC in
healthy volunteers challenged with lipopolysaccharide
Figure 2 APC-overexpression does not impact on lung pathology but attenuates neutrophil influx into the lungs. Histology scores were
similar in WT and APChigh-mice 6, 24 and 48 hours post-infection with 5*104 CFU of S. pneumoniae (A). Representative photographs of WT (B)
and APChigh-mice (C) (H&E staining, original magnification x100) 48 hours post-infection. Decreased granulocyte influx as measured by Ly-6G
expression in APChigh-mice infected with S. pneumoniae, 24 hours after infection (D). Representative photographs of Ly-6G immunostaining
(original magnification x100) for granulocytes of WT (E) and APChigh-mice (F), 24 hours post-infection. APChigh-mice showed decreased numbers
of total cell counts in bronchoalveolar lavage fluid (BALF) compared to WT mice (G), which was caused by a decreased influx of neutrophils
(H). No differences in influx of macrophages (I) and lymphocytes (J) were found. Data are expressed as box and whisker plots showing the
smallest observation, lower quartile, median, upper quartile and largest observation. Numbers of Ly-6G + granulocytes are expressed as the
percentage of the total lung surface area. Neutrophils, macrophages and lymphocytes are expressed as absolute numbers. Grey boxes
represent WT mice, white boxes represent APChigh-mice (n =8 mice per group for each time point). *P <0.05 and **P <0.01 for WT versus
APChigh-mice (Mann–Whitney U test).
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(LPS) by bronchoscopy resulted in decreased neutrophil
migration [35]. In a nice series of experiments involving
both in vivo (LPS challenge in mice) and in vitro experi-
ments (neutrophil agarose migration assay) APC was
shown to desensitize neutrophils for chemotaxis in an
integrin-dependent manner, without affecting neutrophil
function, cytokine production or apoptosis [30]. Here, we
observed a similar specific inhibitory effect of APC affect-
ing the influx of neutrophils when using live bacteria in-
stead of LPS. This effect of APC was observed at 24 hours
after inoculation of S. pneumoniae, while at the 48-hour
time point neutrophil numbers in lungs and KC levels in
lung homogenates and BALF were similar in both mouse
strains, suggesting that during fulminant pneumonia the
inhibitory effect of APC on neutrophil recruitment is over-
ruled by the strong proinflammatory stimulus provided by
high bacterial loads. We did not observe differences in
cytokine levels between APChigh and WT mice, suggestive
of similar chemotactic gradients. In accordance, APC has
been shown to inhibit IL-8 directed [33] and integrin-
Table 1 Cytokine concentrations in lung homogenates and plasma of WT and APChigh-mice during pneumococcal
pneumonia
Lung homogenates
all [pg/ml] WT APChigh WT APChigh WT APChigh
T = 6 T = 24 T = 48
TNF-α 8.6 7.6 249 284 217 56
(6.1-9.8) (4.8-14) (164–318) (182–549) (19–821) (11–290)
IL-6 21 31 1218 1429 1317 694
(17–22) (16–51) (474–1522) (1078–1992) (650–1722) (104–1449)
IL-10 16 24 17 12 20 19
(15–22) (22–35) (11–24) (7.6-21) (11–33) (16–28)
IL-12p70 BD BD 13 17 BD BD
(5.4-21) (11–49)
IFN-γ BD BD 12 19 14 13
(8.1-19) (8.4-26) (4.3-32) (5.4-41)
MCP-1 254 210 2891 3239 4913 3056
(229–274) (187–247) (1935–3561) (2507–4730) (2901–5574) (884–5958)
KC 255 221 4809 6838 8338 6993
(215–317) (66–347) (3548–7702) (5165–9143) (4703–10317) (4421–8496)
KC (BALF) 117 102 255 277 231 236
(106–131) (99–127) (241–347) (252–306) (213–343) (194–260)
Plasma
WT APChigh WT APChigh WT APChigh
T = 6 T = 24 T = 48
TNF-α 15 16 42 37 92 43
(13–20) (13–18) (36–53) (29–46) (48–111) (23–74)
IL-6 5.1 3.9 331 263 795 223
(2.5-7.4) (2.9-22) (232–442) (213–354) (183–881) (111–602)
IL-10 BD BD BD BD BD BD
IL-12p70 7.8 10 11 27 6.9 6.0
(5.2-9.8) (6.4-13) (10–16) (14–40) (3.5-17) (3.9-8.4)
IFN-γ 2.0 1.4 24 38 43 29
(1.9-2.1) (1.3-6.7) (14–41) (23–55) (30–69) (8.2-82)
MCP-1 26 37 138 95 590 240
(26–41) (35–42) (71–196) (83–149) (402–786) (138–786)
Lung and plasma cytokine levels after intranasal infection with 5*105 CFU of S. pneumoniae. Wild type (WT) and APChigh-mice were sacrificed 6, 24 or 48 hours
after infection. Data are expressed as median (interquartile range) of n =8 mice per group per time point. BALF broncho-alveolar lavage fluid, BD below detection
limits, TNF-α tumor necrosis factor-α, IL interleukin, IFN-γ interferon-γ, KC keratinocyte-derived chemokine, MCP-1 monocyte chemotactic protein.
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mediated neutrophil migration [30]. In addition, a recent
study showed that APC might control inflammation via
leukocyte adhesion in a RAGE-dependent way [36]. Of
note, the decreased amount of pulmonary neutrophils did
not result in increased local CFU counts, suggesting that
the number of neutrophils was still adequate to cope with
the pneumococci in the lungs.
Although bacterial loads were comparable at the pri-
mary site of infection, APChigh-mice had lower burdens
of pneumococci in liver and spleen. The endothelium is
the anatomical barrier that pathogens need to cross
before dissemination from the lungs to the systemic
compartment and distant organs. The integrity of the
endothelium is tightly regulated, in which sphingosin-1-
phosphatase (S1P) plays an important part [37]. APC is
able to exert S1P agonistic effects and thereby to im-
prove endothelial barrier function [38], which may in
part explain the reduced dissemination of S. pneumoniae
from the lungs of APChigh-mice. Of note, APChigh-mice
had higher bacterial loads in liver and spleen when
compared with WT mice in spite of similar bacterial
counts in blood. Conceivable explanations for this dis-
crepancy include the possibility that the small amount of
blood plated for culture (50 μl) yields less representative
results when compared with whole organ homogenates,
due to intermittent bacterial spillage to the circulation
from different organs, and/or the option that high APC
levels have more profound effects on bacterial growth in
the cellular environment of intact organs such as the
liver and spleen. Clearly, high APC levels primarily af-
fected bacterial dissemination, considering that APChigh
and WT mice had similar bacterial burdens at the pri-
mary site of infection.
Remarkably, APChigh-mice did not show attenuated
coagulation compared to WT mice. In our previous
studies using this model of pneumococcal pneumonia
administration of rmAPC did exert anticoagulant effects
[19,20]. Notably, the high intraperitoneal APC doses
(125 μg every 8 hours) used in these earlier investiga-
tions resulted in APC levels one hour post-injection that
were almost 10-fold higher than the APC levels mea-
sured in APChigh-mice [19,20,22]. In addition, the APC
expressed in APChigh-mice is described to have 35% less
anticoagulant effect in vitro. Together, these facts may at
least in part explain the lack of a clear anticoagulant ef-
fect in APChigh-mice with pneumococcal pneumonia.
Nonetheless, in spite of this APChigh-mice displayed a
clear protective phenotype, suggesting that the cytopro-
tective effects of APC were mainly responsible here for.
The current results contrast with our recent investiga-
tion in which we studied APChigh-mice in severe
Gram-negative pneumonia derived sepsis caused by Bur-
kholderia pseudomallei, the causative agent of melioidosis
[22]. APChigh-mice demonstrated enhanced susceptibility
to B. pseudomallei infection compared with WT mice as
indicated by a strongly increased mortality accompanied
by enhanced bacterial loads in the lungs, blood, and
distant organs 48 hours after infection [22]. Although a
clear explanation for these different results is lacking,
clearly, the models and pathogens used differ considerably,
Figure 3 APChigh-mice show an unaltered procoagulant response. Mice were infected intranasally with 5*104 CFU of S. pneumoniae. After 6
and 48 hours levels of TATc were measured in lung homogenates (A) and plasma (B) of WT and APChigh-mice. No differences were seen
between WT and APChigh-mice. Grey boxes represent WT mice, white boxes represent APChigh-mice (n =8 mice per group for each time point).
*P <0.05 for WT versus APChigh-mice (Mann–Whitney U test). NEM not enough material for analysis.
Figure 4 Survival. APChigh-mice show a trend towards a delayed
mortality during pneumococcal pneumonia. Wild type (WT) (n =16)
and APChigh-mice (n =12) were infected intranasally with 5*104
CFU of S. pneumoniae and mortality was assessed every 6 hours,
Comparison between groups was done by using Kaplan-Meier
analysis followed by log rank tests.
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which is very well documented in a wide variety of experi-
mental settings. In fact, this is an interesting point which
may, if true in the human situation, might in part explain
the overall poor efficacy of rhAPC in sepsis trials.
Our study is limited by the fact that we studied only
one infectious dose of a serotype 3 pneumococcus. In
the limited experience we have with lower doses of this
highly virulent bacterial strain the onset of disease was
somewhat postponed without clear differences in the
eventual outcome. Nonetheless, further studies are re-
quired to establish the phenotype of APChigh-mice after
infection with other doses of the S. pneumoniae strain
used here, and with other pneumococcal serotypes. In
addition, APChigh-mice do not adequately mimic the
clinical scenario of continuous intravenous APC infusion
started at the time of already established infection, a set-
ting difficult to accomplish in freely moving mice. As
such, our data cannot be directly extrapolated to the effect
of high APC levels achieved at various durations after
induction of pneumonia. The current results, obtained
with mice exposed to sustained high APC levels, confirm
and extend our earlier results obtained with repeated ad-
ministration of bolus doses of recombinant APC during
pneumococcal pneumonia, resulting in a more artificial
situation of highly variable APC concentrations due to the
short half-life of this protein [19,20].
Conclusions
In summary, this study shows that elevated formation of
human APC improves host defense during experimental
pneumococcal pneumonia with respect to reduced bac-
terial dissemination and mitigated neutrophil influx in
the lungs. Although recombinant APC has been with-
drawn from the market these results support previous
preclinical data showing beneficial effects of APC in ex-
perimental models of sepsis and pneumonia.
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